Table 3.
Univariate and multivariate analyses of aGvHD, CMV infection and overall survival.
| Variables | aGvHD ≥ grade 2 |
|||||
|---|---|---|---|---|---|---|
| CI |
Univariate | Multivariate model #1 | Multivariate model #2 | |||
| % | P | HR(95% C.I.; P) | HR(95% C.I.; P) | HR(95% C.I.; P) | ||
| Donor | ||||||
| Matched sibling | 7 | < 0.01 | 1.0 | 1.0 | - | |
| Haploidentical | 24 | 4.68(1.65 - 13.22; < 0.01) | 9.10(2.26 - 36.61; < 0.01) | - | ||
| Unrelated donor | 9 | 3.71(1.16 - 11.90; 0.03) | 3.60(0.69 - 18.83; 0.13) | - | ||
| Source | ||||||
| Bone marrow | 9 | < 0.01 | 1.0 | - | 1.0 | |
| Peripheral blood | 43 | 3.76(1.49 - 9.45; < 0.01) | - | 9.25(3.45 - 24.82; < 0.01) | ||
| Disease | ||||||
| Malignant | 17 | 0.02 | 1.0 | - | - | |
| Non-malignant | 9 | 0.35(0.14 - 0.90; 0.03) | - | - | ||
| CD3+CD4+ recovery | ||||||
| <200/µL | 20 | 0.01 | 1.0 | 1.0 | 1.0 | |
| ≥200/µL | 3 | 0.23(0.07 - 0.76; 0.01) | 0.24(0.08 - 0.76; 0.01) | 0.28(0.08 - 0.97; 0.04) | ||
| Variables | CMV infection |
|||||
|---|---|---|---|---|---|---|
| CI |
Univariate | Multivariate model #1 | Multivariate model #2 | |||
| % | P | HR(95% C.I.; P) | HR(95% C.I.; P) | HR(95% C.I.; P) | ||
| Sex | ||||||
| Female | 57 | <0.01 | 1.0 | 1.0 | 1.0 | |
| Male | 29 | 0.43(0.24 - 0.77; < 0.01) | 0.26(0.12 - 0.54; < 0.01) | 0.40(0.17 - 0.93; 0.03) | ||
| Donor | ||||||
| Matched sibling | 33 | 0.02 | 1.0 | 0.24(0.09 - 0.61; < 0.01) | 0.35(0.11 - 1.07; 0.06) | |
| Haploidentical | 58 | 2.35(1.24 - 4.47); < 0.01 | 1.0 | 1.0 | ||
| Unrelated donor | 30 | 0.96(0.4 - 2.28; 0.92) | 0.21(0.06 - 0.69; < 0.01) | 0.26(0.07 - 1.07; 0.06) | ||
| Source | ||||||
| Bone marrow | 36 | 0.01 | 1.0 | 1.0 | 1.0 | |
| Peripheral blood | 64 | 2.62(1.19 - 5.74; 0.02) | 2.22(0.83 - 5.94; 0.11) | 2.82(0.88 - 9.02; 0.08) | ||
| Malignant disease | ||||||
| Advanced phase | 56 | 0.03 | 1.0 | - | - | |
| Early phase | 26 | 0.37(0.15 - 0.88; 0.02) | - | - | ||
| ALC D+100 recovery | ||||||
| < 500/µL | 15 | 0.04 | 1.0 | 0.19(0.05 - 0.70; 0.01) | - | |
| ≥ 500/µL | 46 | 3.69(0.91 - 14.9; 0.07) | 1.0 | - | ||
| CD3+CD8+ recovery | ||||||
| <200/µL | 21 | 0.02 | 1.0 | - | 0.31(0.12 - 0.79; 0.01) | |
| ≥200/µL | 46 | 2.84(1.15 - 7.02; 0.02) | - | 1.0 | ||
| Variables | Overall Survival |
|||||
|---|---|---|---|---|---|---|
| Kaplan-Meier |
Univariate | Multivariate model #1 | Multivariate model #2 | |||
| % | P | HR(95% C.I.; P) | HR(95% C.I.; P) | HR(95% C.I.; P) | ||
| Source | ||||||
| Bone marrow | 87 | < 0.01 | 4.68(1.88 - 11.68; < 0.01) | 5.77(1.56 - 21.44; < 0.01) | - | |
| Peripheral blood | 57 | 1.0 | 1.0 | - | ||
| Disease | ||||||
| Malignant | 71 | < 0.01 | 1.0 | - | 1.0 | |
| Non-malignant | 95 | 5.31(1.80 - 15.73; < 0.01) | - | 5.72(1.23 - 26.58; 0.03) | ||
| ALC D+100 recovery | ||||||
| < 500/µL | 69 | 0.02 | 1.0 | 1.0 | 1.0 | |
| ≥ 500/µL | 95 | 3.97(1.15 - 13.73; 0.03) | 3.15(0.89 - 11.19; 0.07) | 3.65(1.05 - 12.71; 0.04) | ||
Statistical analyses were performed using the Gray's test for cumulative incidences; Fine-Gray regression for univariate and multivariate analyses; and Kaplan Meier, log-rank test and Cox regression for survival analysis. Abbreviations: aGvHD, acute graft-versus-host disease; CI, cumulative incidence; CMV, cytomegalovirus; 95% C.I., confidence interval; HR, hazard ratio; P, p-value.